Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells

International Journal of Molecular Sciences

Payal Saxena¹  Peter Grimison¹  John E. J. Rasko²  Heidi Strauss²  Althea Bastian²  Dannel Yeo² 

[1]Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia

[2]Li Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, NSW 2050, Australia

关键词: liquid biopsy;    biomarker;    prognosis;    screening;    stem cell;    organoids;   

DOI  :  10.3390/ijms23031671

来源: DOAJ

【 摘 要 】

Pancreatic ductal adenocarcinoma (PDAC) is the most frequent pancreatic cancer type, characterized by a dismal prognosis due to late diagnosis, frequent metastases, and limited therapeutic response to standard chemotherapy. Circulating tumor cells (CTCs) are a rare subset of tumor cells found in the blood of cancer patients. CTCs has the potential utility for screening, early and definitive diagnosis, prognostic and predictive assessment, and offers the potential for personalized management. However, a gold-standard CTC detection and enrichment method remains elusive, hindering comprehensive comparisons between studies. In this review, we summarize data regarding the utility of CTCs at different stages of PDAC from early to metastatic disease and discuss the molecular profiling and culture of CTCs. The characterization of CTCs brings us closer to defining the specific CTC subpopulation responsible for metastasis with the potential to uncover new therapies and more effective management options for PDAC.

【 授权许可】

Unknown